Skip to main content
Home Clinical Trials

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

See what’s new.

https://otc.duke.edu/wp-content/uploads/2024/06/amgen_logo.jpg

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)

Uplizna, an antibody therapy for immune diseases, is based on technology licensed from Duke University, developed by the late Dr. Thomas Tedder (Immunology, SOM) and colleagues.

Read More

https://otc.duke.edu/wp-content/uploads/2024/02/servier-logo.png

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma

This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.

Read More

https://otc.duke.edu/wp-content/uploads/2024/02/citi-program.jpeg

CITI Program Begins Innovative Licensing Partnership with Duke University

Just ASK™ is copyrighted course material developed by Dr. Nadine Barrett (formerly Family Medicine and Community Health, SOM) on how to increase equity and diversity in clinical trials.

Read More

https://otc.duke.edu/wp-content/uploads/2024/01/otc-timeline-announcement-featured-image.jpg

Duke is Inventive: A Century of Innovation at Duke University

A new Centennial physical and digital exhibit from OTC collects innovations, inventors, and companies spinning out of Duke University.

Read More

https://otc.duke.edu/wp-content/uploads/2023/12/Humacyte_Logo.jpg

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma

Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.

Read More

https://otc.duke.edu/wp-content/uploads/2023/11/Servier.jpg

New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/clinetic-logo.png

Clinetic Announces Series A Funding Round Led by Sopris Capital

Clinetic is a medical records Duke start-up founded on technology developed by a team at the Duke Institute for Health Innovation

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/Benner-Study-01@0.25x.png

Newly Identified Lipid in Breast Milk Might Reduce Cerebral Palsy in Infants

Tellus Therapeutics, a neonatal white matter injury therapeutics start-up, was co-founded by Dr. Eric Brenner (Pediatrics, SOM)

Read More

https://otc.duke.edu/wp-content/uploads/2023/03/evecxia-logo.png

Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301

Evecxia Therapeutics is a Duke University start-up, founded by inventors Drs. Jacob Jacobsen and Marc Caron (Cell Biology, SOM) around their serotonin synthesis amplification therapeutic technology for mental health applications.

Read More

1 2 3 5